Literature DB >> 6726386

Anterior cord decompression and spinal stabilization for patients with metastatic lesions of the spine.

K D Harrington.   

Abstract

Metastatic lesions involving the spine may cause vertebral body collapse, resulting in either spinal instability or neural compression, or both. Progressive destruction of the vertebral body by the tumor may cause increasing spinal instability, leading to a kyphotic deformity and further neural deficit. Anterior decompression allows direct excision of the tumor focus and direct neural decompression. Because of postoperative irradiation, conventional bone grafts are rarely incorporated. Over an 8-year period, 52 patients with spinal instability secondary to metastatic pathological fractures of one or more vertebrae underwent anterior decompression and stabilization by replacement of the affected vertebral bodies with methyl methacrylate, polymerizing in situ. No postoperative external support was required, and the acrylic fixation achieved by this method was not affected adversely by subsequent irradiation to a mean of 4020 rads. Forty patients had major neurological impairment preoperatively and required anterior spinal cord and/or nerve root decompression prior to fixation. Of these, 21 had complete neurological recovery postoperatively, 13 others were improved significantly, five remain unchanged, and one patient deteriorated neurologically. There were three cases with failure of fixation. Seven other patients did not benefit from the procedure because of specific complications or the advanced state of their disease. The remaining 42 patients had good relief of pain and restoration of spinal stability, which did not deteriorate during the follow-up period, ranging from 6 to 100 months postoperatively.

Entities:  

Mesh:

Year:  1984        PMID: 6726386     DOI: 10.3171/jns.1984.61.1.0107

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  37 in total

1.  Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study.

Authors:  W Boogerd; J J van der Sande; R Kröger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 2.  Cervical spine metastases: techniques for anterior reconstruction and stabilization.

Authors:  Christina M Sayama; Meic H Schmidt; Erica F Bisson
Journal:  Neurosurg Rev       Date:  2012-04-29       Impact factor: 3.042

3.  A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease.

Authors:  Paul Klimo; Clinton J Thompson; John R W Kestle; Meic H Schmidt
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

4.  Surgical treatment of extradural spinal cord compression due to metastatic tumours.

Authors:  M Coraddu; G C Nurchi; F Floris; V Meleddu
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Spinal surgery.

Authors:  R Johnston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

6.  Neurosurgical Invasive Techniques for Cancer Pain: A Pain Specialist's View.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

7.  Prognostic factors in anterior decompression for metastatic cord compression. An analysis of results.

Authors:  E Sucher; J Y Margulies; Y Floman; G C Robin
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

8.  Posterior stabilization of C2 metastases by combination of atlantoaxial screw fixation and hook plate.

Authors:  H Hertlein; T Mittlmeier; M Schürmann; G Lob
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

Review 9.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Spinal stabilization for patients with metastatic lesions of the spine using a titanium spacer.

Authors:  H Hertlein; T Mittlmeier; S Piltz; M Schürmann; T Kauschke; G Lob
Journal:  Eur Spine J       Date:  1992-09       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.